Literature DB >> 22860170

Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.

Albert J Robichaud1, Darren W Engers, Craig W Lindsley, Corey R Hopkins.   

Abstract

This Review describes recent activity in the advancement of ligands for the metabotropic glutamate 4 receptor subtype and their potential utility as central nervous system (CNS) therapeutics. Until recently, there was a paucity of compounds with suitable selectivity and druglike properties to elucidate the value of this target. The search for selective entities has led several groups to the investigation of allosteric modulators as a path to optimization of potential ligands. Recent efforts, discussed here, have afforded a variety of derivatives with improvements in potency, solubility, and pharmacokinetic properties that garner support for continued investigation and optimization.

Entities:  

Keywords:  Class C GPCR; Metabotropic glutamate receptor 4; Parkinson’s disease; allosteric modulator; anxiety; cognitive disorders; neurodegenerative disorders; orthosteric ligand; pain; psychiatric disorders

Mesh:

Substances:

Year:  2011        PMID: 22860170      PMCID: PMC3369748          DOI: 10.1021/cn200043e

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  67 in total

1.  Exploration of structure-based drug design opportunities for mGluRs.

Authors:  Sid Topiol; Michael Sabio; Michelle Uberti
Journal:  Neuropharmacology       Date:  2010-08-10       Impact factor: 5.250

2.  Integrated synthetic, pharmacological, and computational investigation of cis-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid enantiomers as positive allosteric modulators of metabotropic glutamate receptor subtype 4.

Authors:  Christo Christov; Patricia González-Bulnes; Fanny Malhaire; Tatyana Karabencheva; Cyril Goudet; Jean-Philippe Pin; Amadeu Llebaria; Jesús Giraldo
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

Review 3.  Metabotropic glutamate receptors.

Authors:  Francesco Ferraguti; Ryuichi Shigemoto
Journal:  Cell Tissue Res       Date:  2006-07-18       Impact factor: 5.249

4.  The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.

Authors:  J Konieczny; J Wardas; K Kuter; A Pilc; K Ossowska
Journal:  Neuroscience       Date:  2007-01-16       Impact factor: 3.590

5.  Structures of the extracellular regions of the group II/III metabotropic glutamate receptors.

Authors:  Takanori Muto; Daisuke Tsuchiya; Kosuke Morikawa; Hisato Jingami
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

6.  Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  Giuseppe Battaglia; Carla L Busceti; Gemma Molinaro; Francesca Biagioni; Anna Traficante; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

7.  Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats.

Authors:  Darren W Engers; Julie R Field; Uyen Le; Ya Zhou; Julie D Bolinger; Rocio Zamorano; Anna L Blobaum; Carrie K Jones; Satyawan Jadhav; C David Weaver; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  J Med Chem       Date:  2011-01-19       Impact factor: 7.446

8.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Authors:  Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

Review 9.  Mood disorders: regulation by metabotropic glutamate receptors.

Authors:  Andrzej Pilc; Shigeyuki Chaki; Gabriel Nowak; Jeffrey M Witkin
Journal:  Biochem Pharmacol       Date:  2007-10-05       Impact factor: 5.858

10.  Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.

Authors:  Deborah H Slee; Xiaohu Zhang; Manisha Moorjani; Emily Lin; Marion C Lanier; Yongsheng Chen; Jaimie K Rueter; Sandra M Lechner; Stacy Markison; Siobhan Malany; Tanya Joswig; Mark Santos; Raymond S Gross; John P Williams; Julio C Castro-Palomino; María I Crespo; Maria Prat; Silvia Gual; José-Luis Díaz; Jenny Wen; Zhihong O'Brien; John Saunders
Journal:  J Med Chem       Date:  2008-01-12       Impact factor: 7.446

View more
  17 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Authors:  Joseph D Panarese; Darren W Engers; Yong-Jin Wu; Joanne J Bronson; John E Macor; Aspen Chun; Alice L Rodriguez; Andrew S Felts; Julie L Engers; Matthew T Loch; Kyle A Emmitte; Arlindo L Castelhano; Michael J Kates; Michael A Nader; Carrie K Jones; Anna L Blobaum; P Jeffrey Conn; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2018-10-16       Impact factor: 4.345

3.  Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).

Authors:  Rocco D Gogliotti; Anna L Blobaum; Ryan M Morrison; J Scott Daniels; James M Salovich; Yiu-Yin Cheung; Alice L Rodriguez; Matthew T Loch; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2016-05-11       Impact factor: 2.823

Review 4.  Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  Darren W Engers; Craig W Lindsley
Journal:  Drug Discov Today Technol       Date:  2013

5.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Authors:  Douglas J Sheffler; Cody J Wenthur; Joshua A Bruner; Sheridan J S Carrington; Paige N Vinson; Kiran K Gogi; Anna L Blobaum; Ryan D Morrison; Mitchell Vamos; Nicholas D P Cosford; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

Review 6.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

7.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).

Authors:  Cody J Wenthur; Ryan Morrison; Andrew S Felts; Katrina A Smith; Julie L Engers; Frank W Byers; J Scott Daniels; Kyle A Emmitte; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

8.  Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.

Authors:  Rocco D Gogliotti; Darren W Engers; Pedro M Garcia-Barrantes; Joseph D Panarese; Patrick R Gentry; Anna L Blobaum; Ryan D Morrison; J Scott Daniels; Analisa D Thompson; Carrie K Jones; P Jeffrey Conn; Colleen M Niswender; Craig W Lindsley; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2016-04-19       Impact factor: 2.823

9.  Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability.

Authors:  Zhaoda Zhang; Kun-Eek Kil; Pekka Poutiainen; Ji-Kyung Choi; Hye-Jin Kang; Xi-Ping Huang; Bryan L Roth; Anna-Liisa Brownell
Journal:  Bioorg Med Chem Lett       Date:  2015-07-17       Impact factor: 2.823

10.  Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.

Authors:  Andrew S Felts; Alice L Rodriguez; Katrina A Smith; Julie L Engers; Ryan D Morrison; Frank W Byers; Anna L Blobaum; Charles W Locuson; Sichen Chang; Daryl F Venable; Colleen M Niswender; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  J Med Chem       Date:  2015-11-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.